First of its kind therapy approved for reducing LDL cholesterol. Leqvio, aka Inclisiran, is the first small interfering RNA (siRNA) therapy to hit the market for treating atherosclerotic cardiovascular disease. The regimen consists of an initial subcutaneous injection, another at three months, then a maintenance dose every six months. This treatment reduced LDL by 50%
Parvathy Sukumaran 
